D. Boral Capital initiated coverage of Tevogen (TVGN) with a Buy rating and $10 price target The clinical-stage biotechnology company is developing precision T cell immunotherapies for viral infections, oncology, and neurodegenerative diseases and lead candidate, TVGN-489, is designed to provide targeted immune protection for high-risk COVID-19 patients, the analyst tells investors. The firm believes Tevogen is “positioned to drive innovation in the evolving cell therapy landscape” with a strong intellectual property portfolio and an experienced leadership team, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen CEO addresses broader implications of short-selling
- Biotech Alert: Searches spiking for these stocks today
- Tevogen Bio Holdings Secures Funding for Therapeutics and AI
- Tevogen receives initial $2M grant, may receive $8M more at future date
- Tevogen Bio announces AI collaboration with Microsoft